Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Griffin

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Blood|April 9, 2016
Blood's 70th anniversary: arsenic--from poison pill to magic bulletJames D Griffin
Nature Biotechnology|March 15, 2005
Interaction maps for kinase inhibitorsJames D Griffin
The Hematology Journal : the Official Journal of the European Haematology Association|June 11, 2004
FLT3 tyrosine kinase as a target in acute leukemiasJames D Griffin
Lancet (London, England)|February 21, 2002
Resistance to targeted therapy in leukaemiaJames D Griffin
Seminars in Hematology|June 5, 2003
Molecular mechanisms of transformation by the BCR-ABL oncogeneMartin Sattler, James D Griffin
Seminars in Cancer Biology|August 4, 2004
Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesisLizi Wu, James D Griffin
Oncogene|May 29, 2002
Tyrosine kinase oncogenes in normal hematopoiesis and hematological diseaseBlanca Scheijen, James D Griffin
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|December 4, 2003
Resistance to imatinib (Glivec): update on clinical mechanismsEllen Weisberg, James D Griffin
Genes & Cancer|July 23, 2011
Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent MannerJingrui Jiang, James D Griffin
Cancer Cell|November 3, 2009
JAK2 gets histone H3 rollingMartin Sattler, James D Griffin
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Blood|April 9, 2016
Blood's 70th anniversary: arsenic--from poison pill to magic bulletJames D Griffin
Nature Biotechnology|March 15, 2005
Interaction maps for kinase inhibitorsJames D Griffin
The Hematology Journal : the Official Journal of the European Haematology Association|June 11, 2004
FLT3 tyrosine kinase as a target in acute leukemiasJames D Griffin
Lancet (London, England)|February 21, 2002
Resistance to targeted therapy in leukaemiaJames D Griffin
Seminars in Hematology|June 5, 2003
Molecular mechanisms of transformation by the BCR-ABL oncogeneMartin Sattler, James D Griffin
Seminars in Cancer Biology|August 4, 2004
Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesisLizi Wu, James D Griffin
Oncogene|May 29, 2002
Tyrosine kinase oncogenes in normal hematopoiesis and hematological diseaseBlanca Scheijen, James D Griffin
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|December 4, 2003
Resistance to imatinib (Glivec): update on clinical mechanismsEllen Weisberg, James D Griffin
Genes & Cancer|July 23, 2011
Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent MannerJingrui Jiang, James D Griffin
Cancer Cell|November 3, 2009
JAK2 gets histone H3 rollingMartin Sattler, James D Griffin
Pageof 16